Charles Schwab Investment Management Inc. Invests $503,000 in Inhibrx, Inc. (NASDAQ:INBX)

Charles Schwab Investment Management Inc. acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 32,657 shares of the company’s stock, valued at approximately $503,000. Charles Schwab Investment Management Inc. owned 0.23% of Inhibrx as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in INBX. Bank of New York Mellon Corp purchased a new position in Inhibrx in the fourth quarter valued at about $792,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Inhibrx in the 4th quarter valued at approximately $348,000. Rhumbline Advisers acquired a new position in Inhibrx during the fourth quarter worth $228,000. Exchange Traded Concepts LLC purchased a new position in shares of Inhibrx in the fourth quarter valued at $148,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Inhibrx during the 4th quarter worth $53,000. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Inhibrx Stock Down 0.9 %

INBX stock opened at $13.99 on Tuesday. The stock’s 50 day moving average price is $13.37 and its 200 day moving average price is $14.59. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $35.42.

Inhibrx (NASDAQ:INBX) last posted its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. On average, research analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.